BKT140

立即咨询

BKT140

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

664334-36-5

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
25mg	电议

产品介绍

化学性质

Storage	Store at -20°C
M.Wt	2159.52
Cas No.	664334-36-5
Formula	C₉₇H₁₄₄FN₃₃O₁₉S₂
Solubility	≥216 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic; ≥52.4 mg/mL in H2O
Chemical Name	(3S,6S,9S,12R,17R,20S,23S,26S,29S,34aS)-N-((S)-1-amino-5-guanidino-1-oxopentan-2-yl)-26,29-bis(4-aminobutyl)-17-((S)-2-((S)-2-((S)-2-(4-fluorobenzamido)-5-guanidinopentanamido)-5-guanidinopentanamido)-3-(naphthalen-2-yl)propanamido)-6-(3-guanidinopropyl)-
Canonical SMILES	NCCCC[C@@H]1NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](Cc5ccc6ccccc6c5)NC
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

BKT140, also known as BL-8040 and TF 14016, is an orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity [1].

The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCR4 has been involved in promoting tumor progression. CXCR4 expression is a prognostic marker in various types of cancer, such as acute myelogenous leukemia or breast carcinoma. CXCR4 acts as an important molecule involved in the spread and progression of a variety of different tumors [2].

BKT140 reduced the colony-forming capacity of non-small cell lung cancer (NSCLC) cells. Subcutaneous administration of BKT140 significantly delayed the development of H460 xenografts and showed a similar trend for A549 xenografts [1]. Pre-clinical studies in animal models with BKT140 showed a robust mobilization of white blood cells (WBC) and hematopoietic stem cells (HSC). BKT140 showed a direct anti-tumor effect against human-derived multiple myeloma (MM), lymphoma and primary leukemia cells and cell lines in vitro and in vivo, causing significant apoptosis [2]. BKT140 was well tolerated and rapidly absorbed in patients with multiple myeloma. BKT140 administration significantly increased the number of peripheral blood neutrophils, monocytes, lymphocytes, and CD34+ cells in a dose-dependent manner [3].

References:
[1] Fahham D, Weiss I D, Abraham M, et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer[J]. The Journal of thoracic and cardiovascular surgery, 2012, 144(5): 1167-1175. e1.
[2] Burger J A, Kipps T J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment[J]. Blood, 2006, 107(5): 1761-1767.
[3] Nagler A, Shimoni A, Avivi I, et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation[J]. Blood, 2010, 116(21): 2260-2260.